Breaking News, Financial News

4Q Financial Reports: Bristol-Myers Squibb

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 4Q Revenues: $5 billion (-3%) 4Q Earnings: $499 million (+259%) FY Revenues: $19 billion (-1%) FY Earnings: $3 billion (+25%) Comments: Orencia was approved for the treatment of RA symptoms in the quarter. Worldwide pharmaceutical sales decreased 3% to $4 billion in the quarter. Sales of Plavix increased 11% to $1 billion in the quarter; sales of Avapro/Avalide increased 7% to $277 million in the quarter; total revenue for Abilify increased 17% to $224 mill...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters